{"id":1921,"date":"2022-05-04T15:47:00","date_gmt":"2022-05-04T14:47:00","guid":{"rendered":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/?p=1921"},"modified":"2026-01-26T15:02:23","modified_gmt":"2026-01-26T15:02:23","slug":"amphista-announces-collaborations-potentially-worth-2-billion","status":"publish","type":"post","link":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/2022\/05\/04\/amphista-announces-collaborations-potentially-worth-2-billion\/","title":{"rendered":"Amphista announces collaborations potentially worth $2 billion"},"content":{"rendered":"
\"\"<\/figure>\n<\/p>\n

University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.<\/p>\n

As part of separate partnerships, Amphista will collaborate with Merck Healthcare and Bristol Myers Squibb to leverage the company\u2019s targeted protein degradation (TPD) technology and generate therapeutics in multiple disease areas.<\/p>\n

Merck and Amphista will work to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology. Amphista will receive an upfront payment and R&D funding of up to $44 million, with success-based milestone payments of up to $1 billion.<\/p>\n

Amphista will also receive an upfront payment of $30 million from Bristol Myers Squibb, with potential additional payments of up to $1.25 billion. Bristol Myers Squibb will be granted a global exclusive license to the degraders developed as part of the collaboration and will be responsible for further development and commercialisation activities.<\/p>\n

Amphista creates first-in-class therapeutics that harness the body\u2019s natural processes to degrade and remove disease-causing proteins selectively and efficiently. The company is a spinout from the lab of Professor Alessio Ciulli at the University\u2019s School of Life Sciences.<\/p>\n

Nicola Thompson, CEO of Amphista, said, \u201cWe are extremely pleased to enter into these collaborations, which are a validation of the progress we have made in TPD research and the potential of our EclipsysTM next-generation TPD platform.\u201d<\/p>\n

TPD exploits the body\u2019s own cellular waste disposal system to destroy disease-causing proteins, rather than inhibiting their function. This new approach provides hope of treating diseases previously thought to be undruggable and is applicable to diverse areas including oncology, dermatology, immunology, respiratory and central nervous system diseases.<\/p>\n

Degrading rather than inhibiting a target protein offers several advantages such as better drug response at lower doses as well as reduced side effects and disease resistance.<\/p>\n

Amphista\u2019s technology is specifically designed to develop next generation TPD therapeutics based on mechanistic insights and novel chemistry approaches that enable the company to develop novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability.<\/p>\n

About Amphista Therapeutics<\/h2>\n

Amphista Therapeutics is a global leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, addressing the challenges faced by the field to realise the full potential of this transformational modality.<\/p>\n

The company\u2019s proprietary EclipsysTM Platform supports development of multiple innovative therapeutic candidates able to overcome the limitations associated with traditional TPD approaches with superior levels of efficacy and broad therapeutic applicability. The Amphista team includes pioneers and established leaders in TPD research and in drug discovery and development. The company is supported by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.<\/p>\n

For more information, please visit\u00a0http:\/\/www.amphista.com\/<\/a>.<\/p>\n

Related links<\/h2>\n